000650 仁和药业
已收盘 04-11 15:00:00
资讯
新帖
简况
仁和药业出资800万元成立江西仁和医药投资有限公司，持股80%
金融界 · 03-11
仁和药业出资800万元成立江西仁和医药投资有限公司，持股80%
仁和药业：2023年公司董事长进行了增持，2024年公司进行了回购，目前暂无回购增持计划
证券之星 · 03-10
仁和药业：2023年公司董事长进行了增持，2024年公司进行了回购，目前暂无回购增持计划
仁和药业最新公告：子公司获得盐酸莫西沙星滴眼液药品注册证书
证券之星 · 03-10
仁和药业最新公告：子公司获得盐酸莫西沙星滴眼液药品注册证书
仁和药业(000650.SZ)：盐酸莫西沙星滴眼液获得药品注册证书
智通财经 · 03-10
仁和药业(000650.SZ)：盐酸莫西沙星滴眼液获得药品注册证书
仁和药业：2024年前三季度公司净利4.16亿，药品+大健康品双主营业务基本面无变化
证券之星 · 03-05
仁和药业：2024年前三季度公司净利4.16亿，药品+大健康品双主营业务基本面无变化
仁和药业：公司不存在破产重组的问题，药品+大健康品双主营业务基本面无变化
证券之星 · 03-05
仁和药业：公司不存在破产重组的问题，药品+大健康品双主营业务基本面无变化
仁和药业：影响股价的因素很多，有公司自身因素、行业因素、宏观经济与市场等因素
证券之星 · 03-05
仁和药业：影响股价的因素很多，有公司自身因素、行业因素、宏观经济与市场等因素
仁和药业：截止2025年2月28日，大约11万户左右。具体数据请向公司证券部提交股东身份证明
证券之星 · 03-04
仁和药业：截止2025年2月28日，大约11万户左右。具体数据请向公司证券部提交股东身份证明
仁和药业：影响股价的因素很多，有公司自身因素、行业因素、宏观经济与市场等因素
证券之星 · 02-27
仁和药业：影响股价的因素很多，有公司自身因素、行业因素、宏观经济与市场等因素
仁和药业：2024年披露获得磷酸奥司他韦胶囊、二冬汤颗粒等批文的公告
证券之星 · 02-21
仁和药业：2024年披露获得磷酸奥司他韦胶囊、二冬汤颗粒等批文的公告
仁和药业（000650）2月19日主力资金净买入119.32万元
证券之星 · 02-20
仁和药业（000650）2月19日主力资金净买入119.32万元
仁和药业：叮当快药与公司是同一实际控制人的关系
证券之星 · 02-18
仁和药业：叮当快药与公司是同一实际控制人的关系
仁和药业：目前没有接入幻方大模型系统
证券之星 · 02-14
仁和药业：目前没有接入幻方大模型系统
仁和药业：截止2025年1月27日，大约11万户左右。具体数据需提交股东身份证明
证券之星 · 02-05
仁和药业：截止2025年1月27日，大约11万户左右。具体数据需提交股东身份证明
仁和药业：截止2025年1月20日，大约11万户左右。具体数据请提交股东身份证明
证券之星 · 02-03
仁和药业：截止2025年1月20日，大约11万户左右。具体数据请提交股东身份证明
仁和药业：公司有较多品类品规的抗病毒、感冒、止咳等相关产品的生产和销售
证券之星 · 01-09
仁和药业：公司有较多品类品规的抗病毒、感冒、止咳等相关产品的生产和销售
仁和药业：公司磷酸奥司他韦胶囊等抗流感药品市场供应充足
美港电讯 · 01-09
仁和药业：公司磷酸奥司他韦胶囊等抗流感药品市场供应充足
仁和药业收盘上涨0.34%，滚动市盈率18.63倍
金融界 · 2024-12-25
仁和药业收盘上涨0.34%，滚动市盈率18.63倍
12月13日仁和药业现1笔大宗交易 机构净买入202.01万元
证券之星 · 2024-12-13
12月13日仁和药业现1笔大宗交易 机构净买入202.01万元
仁和药业获全国首批中药经典名方“二冬汤颗粒”
证券之星 · 2024-11-11
仁和药业获全国首批中药经典名方“二冬汤颗粒”
加载更多
公司概况
公司名称：
仁和药业股份有限公司
所属行业：
医药制造业
上市日期：
1996-12-10
主营业务：
仁和药业股份有限公司主营业务是生产、销售中西药、原料药及健康相关产品。公司主营产品为口服固体制剂、口服液体制剂、大容量注射剂、小容量注射剂、外用洗剂、搽剂、栓剂、软膏剂等剂型药品以及健康相关产品。公司是全国通过GMP认证生产线最多的企业之一。
发行价格：
6.26
{"stockData":{"symbol":"000650","market":"SZ","secType":"STK","nameCN":"仁和药业","latestPrice":5.33,"timestamp":1744355034000,"preClose":5.34,"halted":0,"volume":12759150,"delay":0,"changeRate":-0.0019,"floatShares":1331000000,"shares":1400000000,"eps":0.3162,"marketStatus":"已收盘","change":-0.01,"latestTime":"04-11 15:00:00","open":5.32,"high":5.36,"low":5.29,"amount":67941800,"amplitude":0.0131,"askPrice":5.34,"askSize":2477,"bidPrice":5.33,"bidSize":459,"shortable":0,"etf":0,"ttmEps":0.3162,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1744594200000},"marketStatusCode":5,"adr":0,"adjPreClose":5.34,"symbolType":"stock","openAndCloseTimeList":[[1744335000000,1744342200000],[1744347600000,1744354800000]],"highLimit":5.87,"lowLimit":4.81,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1399938234,"isCdr":false,"pbRate":1.23,"roa":"--","peRate":16.85642,"roe":"6.79%","epsLYR":0.41,"committee":-0.186245,"marketValue":7462000000,"turnoverRate":0.0096,"status":1,"floatMarketCap":7096000000},"requestUrl":"/m/hq/s/000650","defaultTab":"news","newsList":[{"id":"2518751210","title":"仁和药业出资800万元成立江西仁和医药投资有限公司，持股80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518751210","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518751210?lang=zh_cn&edition=full","pubTime":"2025-03-11 12:18","pubTimestamp":1741666708,"startTime":"0","endTime":"0","summary":"天眼查工商信息显示，近日，仁和药业股份有限公司出资800万元成立江西仁和医药投资有限公司，持股80%，所属行业为资本市场服务。资料显示，江西仁和医药投资有限公司成立于2025年3月10日，法定代表人为朱凌云，注册资本1000万人民币，公司位于宜春市，以自有资金从事投资活动，企业管理咨询，企业管理（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/11121848651237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0188","000650","BK0239","BK1515","BK1574","09939","BK1161","159938","BK0097"],"gpt_icon":0},{"id":"2518422932","title":"仁和药业：2023年公司董事长进行了增持，2024年公司进行了回购，目前暂无回购增持计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2518422932","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518422932?lang=zh_cn&edition=full","pubTime":"2025-03-10 20:51","pubTimestamp":1741611110,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业03月10日在投资者关系平台上答复投资者关心的问题。后续公司是否有回购增持计划？2023年公司董事长进行了增持，2024年公司进行了回购，目前暂无回购增持计划。依据公司第二期员工持股计划方案，关于2024年度能否业绩等达标，请于2025年4月26日查阅公司2024年度报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000031739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0097","BK0188","BK0239"],"gpt_icon":0},{"id":"2518216049","title":"仁和药业最新公告：子公司获得盐酸莫西沙星滴眼液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2518216049","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518216049?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:54","pubTimestamp":1741596856,"startTime":"0","endTime":"0","summary":"仁和药业(000650.SZ)公告称，公司子公司江西闪亮制药有限公司收到国家药品监督管理局核准签发的盐酸莫西沙星滴眼液《药品注册证书》。该药品为处方药，临床用于敏感微生物引起的细菌性结膜炎的治疗，为医保目录乙类药物。盐酸莫西沙星滴眼液以化学药品4类获批上市，标志着此产品视同通过仿制药一致性评价。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000022067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","000650","BK0097"],"gpt_icon":0},{"id":"2518297257","title":"仁和药业(000650.SZ)：盐酸莫西沙星滴眼液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2518297257","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518297257?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:00","pubTimestamp":1741593601,"startTime":"0","endTime":"0","summary":"智通财经APP讯，仁和药业(000650.SZ)发布公告，公司子公司江西闪亮制药有限公司近日收到国家药品监督管理局核准签发的关于盐酸莫西沙星滴眼液《药品注册证书》。盐酸莫西沙星滴眼液临床用于敏感微生物(包括：革兰氏阳性菌、革兰氏阴性菌、沙眼衣原体等)引起的细菌性结膜炎的治疗，为医保目录乙类药物。本次盐酸莫西沙星滴眼液以化学药品4类获批上市，标志着此产品视同通过仿制药一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0097","BK0239","BK0188","000650"],"gpt_icon":0},{"id":"2517966691","title":"仁和药业：2024年前三季度公司净利4.16亿，药品+大健康品双主营业务基本面无变化","url":"https://stock-news.laohu8.com/highlight/detail?id=2517966691","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517966691?lang=zh_cn&edition=full","pubTime":"2025-03-05 15:07","pubTimestamp":1741158437,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业03月05日在投资者关系平台上答复投资者关心的问题。公司股票从年初到现在一直破位下跌，按照目前跌幅速度，年底前后跌破1元的概率很大。影响股价的因素很多，有公司自身因素、行业因素、宏观经济与市场等因素，2020年至2023年，公司年平均净利润维持在5-6亿左右，2024年前三季度公司净利4.16亿，目前公司药品+大健康品双主营业务基本面没有任何变化，无应披露而未披露的信息。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030500020603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000650","BK0097","BK0239"],"gpt_icon":0},{"id":"2517517966","title":"仁和药业：公司不存在破产重组的问题，药品+大健康品双主营业务基本面无变化","url":"https://stock-news.laohu8.com/highlight/detail?id=2517517966","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517517966?lang=zh_cn&edition=full","pubTime":"2025-03-05 15:07","pubTimestamp":1741158437,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业03月05日在投资者关系平台上答复投资者关心的问题。影响股价的因素很多，有公司自身因素、行业因素、宏观经济与市场等因素，2020年至2023年，公司年平均净利润维持在5-6亿左右，2024年前三季度公司净利4.16亿，公司药品+大健康品双主营业务基本面没有任何变化，无应披露而未披露的信息。目前，公司不存在破产重组的问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030500020602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","BK0188","000650"],"gpt_icon":0},{"id":"2517966396","title":"仁和药业：影响股价的因素很多，有公司自身因素、行业因素、宏观经济与市场等因素","url":"https://stock-news.laohu8.com/highlight/detail?id=2517966396","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517966396?lang=zh_cn&edition=full","pubTime":"2025-03-05 15:04","pubTimestamp":1741158252,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业03月05日在投资者关系平台上答复投资者关心的问题。影响股价的因素很多，有公司自身因素、行业因素、宏观经济与市场等因素，2020年至2023年，公司年平均净利润维持在5-6亿左右，2024年前三季度公司净利4.16亿，目前公司药品+大健康品双主营业务基本面没有任何变化，无应披露而未披露的信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030500020318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0239","BK0188","000650"],"gpt_icon":0},{"id":"2516624744","title":"仁和药业：截止2025年2月28日，大约11万户左右。具体数据请向公司证券部提交股东身份证明","url":"https://stock-news.laohu8.com/highlight/detail?id=2516624744","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516624744?lang=zh_cn&edition=full","pubTime":"2025-03-04 19:00","pubTimestamp":1741086015,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业03月04日在投资者关系平台上答复投资者关心的问题。投资者：请问截至2月28日收盘公司股东人数是多少，谢谢！仁和药业董秘：谢谢您的关注，截止2025年2月28日，大约11万户左右。具体数据，根据相关法规，请您先向公司证券部提交股东身份证明，谢谢！最后，公司对创新药研发持积极态度，公司会依据公司的发展情况，适时适机做好上述相关工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030400033881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0097","BK0239","000650"],"gpt_icon":0},{"id":"2514120458","title":"仁和药业：影响股价的因素很多，有公司自身因素、行业因素、宏观经济与市场等因素","url":"https://stock-news.laohu8.com/highlight/detail?id=2514120458","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514120458?lang=zh_cn&edition=full","pubTime":"2025-02-27 11:00","pubTimestamp":1740625221,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业02月27日在投资者关系平台上答复投资者关心的问题。投资者：大盘快逼近3400点了，而公司股价连跌了4年，请公司如实向投资者说明公司股票下跌的原因是什么！影响股价的因素很多，有公司自身因素、行业因素、宏观经济与市场等因素，2020年至2023年，公司年平均净利润维持在5-6亿左右，2024年前三季度公司净利4.16亿，目前公司基本面没有任何变化，无应披露而未披露的信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022700014080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0097","BK0239","BK0188"],"gpt_icon":0},{"id":"2513268760","title":"仁和药业：2024年披露获得磷酸奥司他韦胶囊、二冬汤颗粒等批文的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2513268760","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513268760?lang=zh_cn&edition=full","pubTime":"2025-02-21 18:30","pubTimestamp":1740133827,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业02月21日在投资者关系平台上答复投资者关心的问题。公司在研产品情况建议您查阅2023年度报告全文版里关于研发部分章节，2024年公司也披露获得磷酸奥司他韦胶囊、二冬汤颗粒等批文的公告。公司经营现金流充欲是企业生存与发展、稳健运营的关键。投资者：请问，公司的股票仁和药业市值到达3亿元的计划和目标还有多久？！截止2025年2月21日收盘，公司市值近80亿人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022100034726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000650","BK0239","BK0097"],"gpt_icon":0},{"id":"2512345704","title":"仁和药业（000650）2月19日主力资金净买入119.32万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512345704","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512345704?lang=zh_cn&edition=full","pubTime":"2025-02-20 09:25","pubTimestamp":1740014755,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2025年2月19日收盘，仁和药业报收于5.59元，上涨0.0%，换手率1.0%，成交量13.29万手，成交额7422.86万元。近5日资金流向一览见下表：仁和药业融资融券信息显示，融资方面，当日融资买入900.81万元，融资偿还850.81万元，融资净买入50.0万元，连续3日净买入累计996.31万元。仁和药业主营业务：生产、销售中西药、原料药及健康相关产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022000008061.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0097","BK0188","BK0239"],"gpt_icon":0},{"id":"2512169904","title":"仁和药业：叮当快药与公司是同一实际控制人的关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2512169904","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512169904?lang=zh_cn&edition=full","pubTime":"2025-02-18 11:00","pubTimestamp":1739847620,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)02月18日在投资者关系平台上答复投资者关心的问题。投资者：国家倡导上市公司做好兼并重组，叮当快药快药体验非常好，但好像并非上市公司旗下经营，希望能兼并叮当快药，做优做强，更好地服务于大众。仁和药业董秘：谢谢您的关注！叮当快药与公司的关系是同一实际控制人的关系。建议收到，谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021800014786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1142","BK0097","BK0188","09886","BK1247","000650","BK0239"],"gpt_icon":0},{"id":"2511945657","title":"仁和药业：目前没有接入幻方大模型系统","url":"https://stock-news.laohu8.com/highlight/detail?id=2511945657","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511945657?lang=zh_cn&edition=full","pubTime":"2025-02-14 17:30","pubTimestamp":1739525418,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)02月14日在投资者关系平台上答复投资者关心的问题。投资者：请问公司有没有接入幻方大模型系统。仁和药业董秘：谢谢您的关注！目前没有，公司会持续关注！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021400028124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","000650","BK0188"],"gpt_icon":0},{"id":"2509347255","title":"仁和药业：截止2025年1月27日，大约11万户左右。具体数据需提交股东身份证明","url":"https://stock-news.laohu8.com/highlight/detail?id=2509347255","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509347255?lang=zh_cn&edition=full","pubTime":"2025-02-05 17:00","pubTimestamp":1738746027,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)02月05日在投资者关系平台上答复投资者关心的问题。投资者：请问截止1月27日股东收盘公司人数是多少？谢谢！仁和药业董秘：谢谢您的关注，新年好！截止2025年1月27日，大约11万户左右。具体数据，根据相关法规，请您先向公司证券部提交股东身份证明，谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025020500024108.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0239","BK0188","000650"],"gpt_icon":0},{"id":"2508993721","title":"仁和药业：截止2025年1月20日，大约11万户左右。具体数据请提交股东身份证明","url":"https://stock-news.laohu8.com/highlight/detail?id=2508993721","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508993721?lang=zh_cn&edition=full","pubTime":"2025-02-03 15:00","pubTimestamp":1738566034,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)02月03日在投资者关系平台上答复投资者关心的问题。投资者：请问：1月20日股东人数是多少？谢谢！仁和药业董秘：谢谢您的关注，新年好！截止2025年1月20日，大约11万户左右。具体数据，根据相关法规，请您先向公司证券部提交股东身份证明，谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025020300000879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","000650","BK0239","BK0188"],"gpt_icon":0},{"id":"2502054558","title":"仁和药业：公司有较多品类品规的抗病毒、感冒、止咳等相关产品的生产和销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2502054558","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2502054558?lang=zh_cn&edition=full","pubTime":"2025-01-09 12:50","pubTimestamp":1736398216,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业01月09日在投资者关系平台上答复投资者关心的问题。市场主流的抗流感产品磷酸奥司他韦胶囊我公司已销售多年，且为自研、自产，目前能够保证市场供应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010900017169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","000650","BK0239","BK0188"],"gpt_icon":0},{"id":"2502545059","title":"仁和药业：公司磷酸奥司他韦胶囊等抗流感药品市场供应充足","url":"https://stock-news.laohu8.com/highlight/detail?id=2502545059","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2502545059?lang=zh_cn&edition=full","pubTime":"2025-01-09 12:07","pubTimestamp":1736395623,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0097","518880","SGCmain","BK0188","NUGT","159934","IAU","GCmain","159831","SGUmain","GDX","GLD","DUST","MGCmain","000650","BK0239"],"gpt_icon":0},{"id":"2494111180","title":"仁和药业收盘上涨0.34%，滚动市盈率18.63倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2494111180","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2494111180?lang=zh_cn&edition=full","pubTime":"2024-12-25 16:17","pubTimestamp":1735114622,"startTime":"0","endTime":"0","summary":"12月25日，仁和药业今日收盘5.89元，上涨0.34%，滚动市盈率PE达到18.63倍。从行业市盈率排名来看，公司所处的中药行业市盈率平均41.41倍，行业中值28.16倍，仁和药业排名第28位。股东方面，截至2024年11月29日，仁和药业股东户数110000户，较上次增加0户，户均持股市值35.28万元，户均持股数量2.76万股。仁和药业股份有限公司主营业务是生产、销售中西药、原料药及健康相关产品。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2024/12/25161746795331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0097","BK0239","BK0188","000650"],"gpt_icon":0},{"id":"2491734654","title":"12月13日仁和药业现1笔大宗交易 机构净买入202.01万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491734654","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2491734654?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:49","pubTimestamp":1734079764,"startTime":"0","endTime":"0","summary":"证券之星消息，12月13日仁和药业发生大宗交易，交易数据如下：大宗交易成交价格6.03元，成交33.5万股，成交金额202.01万元，买方营业部为机构专用，卖方营业部为中信证券股份有限公司上海分公司。近三个月该股共发生1笔大宗交易，合计成交3350.0手。该股近期无解禁股上市。截至2024年12月13日收盘，仁和药业(000650)报收于6.03元，下跌2.11%，换手率3.02%，成交量40.25万手，成交额2.45亿元。该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121300028947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0239","BK0188","000650"],"gpt_icon":0},{"id":"2482391783","title":"仁和药业获全国首批中药经典名方“二冬汤颗粒”","url":"https://stock-news.laohu8.com/highlight/detail?id=2482391783","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2482391783?lang=zh_cn&edition=full","pubTime":"2024-11-11 20:19","pubTimestamp":1731327559,"startTime":"0","endTime":"0","summary":"2024年11月，在江西省药品监督管理局、江西省樟树药品监督管理局及江西省药品检验检测研究院的全力指导和帮助下，仁和药业历时7年研发的第一款经典名方产品”二冬汤颗粒“获批上市，仁和药业成为江西省首家获得经典名方批文的企业。什么是经典名方？根据《中华人民共和国中医药法》,古代经典名方是指“至今仍广泛运用、疗效确切、具有明显特色与优势的古代中医典籍所记载的方剂”。目前我国经典名方的开发明显滞后，其主要","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024111100027071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0188","BK0097","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1744591225285,"stockEarnings":[{"period":"1week","weight":-0.0533},{"period":"1month","weight":-0.0379},{"period":"3month","weight":-0.0344},{"period":"6month","weight":-0.1027},{"period":"1year","weight":-0.1506},{"period":"ytd","weight":-0.0747}],"compareEarnings":[{"period":"1week","weight":-0.0311},{"period":"1month","weight":-0.0396},{"period":"3month","weight":0.022},{"period":"6month","weight":0.0064},{"period":"1year","weight":0.0672},{"period":"ytd","weight":-0.0339}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"仁和药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"110000人(较上一季度增加0.00%)","perCapita":"12103股","listingDate":"1996-12-10","address":"江西省宜春市樟树市葛玄路6号","registeredCapital":"139993万元","survey":" 仁和药业股份有限公司主营业务是生产、销售中西药、原料药及健康相关产品。公司主营产品为口服固体制剂、口服液体制剂、大容量注射剂、小容量注射剂、外用洗剂、搽剂、栓剂、软膏剂等剂型药品以及健康相关产品。公司是全国通过GMP认证生产线最多的企业之一。","listedPrice":6.26},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.4","shortVersion":"4.32.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"仁和药业(000650)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供仁和药业(000650)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"仁和药业,000650,仁和药业股票,仁和药业股票老虎,仁和药业股票老虎国际,仁和药业行情,仁和药业股票行情,仁和药业股价,仁和药业股市,仁和药业股票价格,仁和药业股票交易,仁和药业股票购买,仁和药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"仁和药业(000650)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供仁和药业(000650)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}